[2] SYNSORB Biotech Inc. Appoints Vice President, Clinical & Regulatory Affairs.CALGARY, Alberta--(BUSINESS WIRE)--Nov. 22, 1999-- SYNSORB Biotech Inc.(NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :SYBB) (TSE See Tokyo Stock Exchange. TSE 1. See Tokyo Stock Exchange (TSE). 2. See Toronto Stock Exchange (TSE). :SYB a. 1. See Sib. .) SYNSORB Biotech Inc. ("SYNSORB") (TSE: SYB, Nasdaq: SYBB) today announced the appointment of John J. Frey, Ph.D. to the position of Vice President, Clinical & Regulatory Affairs, where his responsibilities will include all matters pertaining to the development and conduct of the company's clinical trials and regulatory filings, as well as its regulatory strategy. Dr. Frey is a business oriented scientist with over 27 years experience in the pharmaceutical industry, including positions with Pfizer Pharmaceuticals, New York New York, state, United States New York, Middle Atlantic state of the United States. It is bordered by Vermont, Massachusetts, Connecticut, and the Atlantic Ocean (E), New Jersey and Pennsylvania (S), Lakes Erie and Ontario and the Canadian province of , NY; Bristol-Myers Pharmaceuticals, New York, NY; Johnson & Johnson: Ortho Pharmaceutical Corporation, Raritan, NJ; and Ciba-Geigy Pharmaceuticals, Summit, NJ. Most recently, Dr. Frey was President and Principal Consultant at Health Products Development, Lancaster, PA, providing consulting and contract services for clinical development through attaining regulatory agency regulatory agency Independent government commission charged by the legislature with setting and enforcing standards for specific industries in the private sector. The concept was invented by the U.S. marketing approvals for prescription health care products. Dr. Frey will relocate to Calgary in early December. Dr. Frey has expertise in a broad range of areas including the management of clinical trials; regulatory submissions; regulatory strategy and regulatory affairs; biostatistics; and pharmaco-epidemiology. In addition, he has directly contributed to the attainment of approval for numerous pharmaceutical products and medical devices at the international level and with the US Food and Drug Administration ("FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. "). "John Frey's experience in the management and successful completion of clinical trials is extremely valuable to SYNSORB at this stage in our clinical development programs," said David Cox, Ph.D., President and Chief Executive Officer of SYNSORB. "His proven track record of success in bringing products to market adds an important element to SYNSORB's executive team. I am very pleased to make this announcement and welcome Dr. Frey to Calgary." SYNSORB is a Canadian-based pharmaceutical company dedicated to drug development and manufacturing. The Company has two late-stage products, both of which are based on SYNSORB's proprietary carbohydrate chemistry platform technology. SYNSORB Pk is in Phase III clinical trials, and is designed to prevent the progression to Hemolytic Uremic Syndrome hemolytic uremic syndrome n. A syndrome in which hemolytic anemia and thrombocytopenia occur with acute renal failure, marked in children by sudden gastrointestinal bleeding, urine that contains red blood cells and is scanty in volume, and (HUS) in children who have contracted verotoxigenic E. coli E. coli: see Escherichia coli. E. coli in full Escherichia coli Species of bacterium that inhabits the stomach and intestines. E. coli can be transmitted by water, milk, food, or flies and other insects. (VTEC VTEC verocytotoxin producing Escherichia coli. ) infections, including E. coli O157:H7. SYNSORB Cd will commence Phase III trials in the first part of next year, and is designed to treat recurrent antibiotic-associated diarrhea (CDAD CDAD Clostridium Difficile-Associated Diarrhea CDAD Component Data Administrator ), a common hospital acquired infection. SYNSORB has built a cGMP-compliant manufacturing facility that has the capacity to meet or exceed the expected global demand for the Company's products. A pipeline of future products is accessible through subsidiary companies and SYNSORB's carbohybrid program. This release contains certain forward-looking statements which involve known and unknown risks, delays, uncertainties and other factors not under the Company's control which may cause actual results, performance or achievements of the Company to be materially different from the results, performance or other expectations implied by these forward-looking statements. These factors include results of current or pending clinical trials, actions by the FDA/HPB and those factors detailed in the Company's registration statement on Form 20 F filed with the Securities and Exchange Commission. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion